To the Editor: The Guidelines for the management of acute coronary syndromes 20061 state: “Enoxaparin may be used in conjunction with fibrin-specific fibrinolytic agents in patients under the age of 75 years, provided they do not have significant renal dysfunction. An intravenous bolus dose of 30 mg followed by a 1 mg/kg subcutaneous injection every 12 hours in combination with tenecteplase is the most comprehensively studied therapy.”1
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- Emergency Department, Caboolture Hospital, Caboolture, QLD.
Correspondence: mark_little@health.qld.gov.au
- 1. Acute Coronary Syndrome Guidelines Working Group. Guidelines for the management of acute coronary syndromes 2006. Med J Aust 2006; 184 (8 Suppl): S1-S32. <MJA full text>
- 2. Enxoaparin. Enoxaparin (Clexane) product information. Sydney: Sanofi-Aventis Australia, 22 June 2005.
Online responses are no longer available. Please refer to our instructions for authors page for more information.